-
1
Poly(ADP-ribosyl)ation (PARylation) is a crucial post-translational modification influencing DNA repair, immune evasion, and therapeutic resistance in ovarian cancer.
-
2
Aberrant glycosylation and immune checkpoints like PD-L1 illustrate how post-translational modifications shape the tumor immune microenvironment.
-
3
Combination therapies targeting PARylation alongside other pathways, such as ATR/CHK1 inhibition and immune checkpoint blockade, are being explored to combat resistance.
-
4
Challenges in clinical translation include patient heterogeneity, overlapping toxicities, and the need for predictive biomarkers beyond BRCA mutation status.
-
5
Understanding the interplay of PARylation with other post-translational modifications is essential for developing effective therapeutic strategies in ovarian cancer.
